P17.02 Durvalumab After chemoRadioTherapy (DART) for NSCLC Patients – a Phase II Translational and Biomarker Study

Abstract

showed a two-fold reduction in peripheral IL-8 gene expression in paired blood samples when compared with the six patients showing progressive disease with available gene expression data. Samples collected during a ceralasertib-only period prior to durvalumab treatment showed modified biomarkers of peripheral immunity including significant increases in antigen presentation gene signature and significant decreases in both exhausted T cell and NK cell signatures from bulk whole-blood RNA samples. Ceralasertib also decreased 4 macrophage gene expression signatures in on-treatment samples. Similar gene expression profiles were not observed from comparable samples on other HUDSON arms. No correlation between ATM biomarker status and RECIST response was observed. No significant correlations with ceralasertib response were observed between tumour mutation burden or PDL1 status by IHC. Conclusion: Taken together, these data support a role of immune activation by ceralasertib as a feature of response to combination therapy with ceralasertib plus durvalumab in NSCLC following progression on anti-PD(L)1.

Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition

“…In the ESR 1814205 CRT-IO feasibility study in poor risk and/or elderly patients with stage III NSCLC, a 18 F-FDG PET/CT is obligatory within 30 days for enrollment (NCT04441138). A phase II translational and biomarker DART study of the Norwegian group has incorporated a serial 18 F-FDG-PET/CT imaging together with collection of tumor tissue as well as blood, urine, and stool samples [38]. For the ICI as a monotherapy in advanced NSCLC, several studies have already reported about a potential of metabolic parameters to predict post-treatment progression [39,40].…”